Transgenomic, Inc. (TBIO) and MD Anderson Collaborate on Circulating Tumor Cell Study Using ICE COLD-PCR  
3/20/2012 8:46:01 AM

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced that it has begun a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the Company’s very high sensitivity ICE COLD-PCR mutation detection technology in analysis of DNA isolated from circulating tumor cells (CTCs) in blood samples from patients with advanced cancer.